6533b838fe1ef96bd12a5213

RESEARCH PRODUCT

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion

Antonino ZarconeMirko LuparelliGiuseppe CoppolaEgle CorradoAntonino MignanoGiuseppina NovoGirolamo Manno

subject

Medicine (General)medicine.medical_specialtymedicine.medical_treatmentElectric CountershockAdministration OralReviewCardioversionDrug Administration ScheduleR5-920Quality of lifeInternal medicineAtrial FibrillationmedicineHumanscardiovascular diseaseselectrical cardioversion (ec)Strokedirect oral anticoagulants (doacs)business.industryWarfarinAnticoagulantsCardiac arrhythmiaAtrial fibrillationGeneral MedicineHeparinmedicine.diseaseatrial fibrillation (af)Shock (circulatory)cardiovascular systemCardiologymedicine.symptombusinessmedicine.drug

description

Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real “epidemic phenomenon”. Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in bleedings and increase in the safety and quality of life of patients.

yearjournalcountryeditionlanguage
2019-09-01Medicina
https://doi.org/10.3390/medicina55100660